Please register here to join.

John Sninsky, PhD, co-founder of Translational HDPM (High Dimensional Precision Medicine) and a SPARK at Stanford advisor, will present on Biomarkers in Preclinical Drug Development: The Drug Development Paradox. 

John was CSO-CIO at Superfluid Dx, an early-stage biotechnology company with a pioneering, disease-agnostic cell-free mRNA platform that uses NGS and machine learning to develop classifiers for compelling unmet clinical needs. Superfluid Dx prioritized Alzheimer’s Disease. John has a comprehensive and deep understanding of the development and application of pioneering molecular procedures and bioinformatics to the translation of research-grade biomarker assays into clinical-grade, broadly adopted diagnostic tests, as well as diagnostic tests paired with pharmacotherapies. John is the author of more than 120 scientific papers, including advanced methods in molecular biology and next-generation sequencing. He was a member of teams that developed the Polymerase Chain Reaction, sequenced the Human Genome, and developed clinical-grade liquid biopsies for transplantation. John spent 30+ years in senior management at companies that ranged from small to enterprise CLIA-CAP laboratories and small to enterprise in vitro diagnostic companies that commercialize FDA-cleared/approved IVD kits. These companies included Cetus, Roche Molecular Systems, Celera Diagnostics, Quest Diagnostics, CareDx and CellMax Life. He lectures in Translational Research, Diagnostic Statistics, Biomedical AI/ML and Regulatory Science for Diagnostics at and advises commercial Precision Medicine translation efforts at Stanford University (SPARK), University of California, San Francisco (CATALYST) and University of California, Berkeley. John mentors Biomedical Data Science projects for the Data Mine at Purdue University, where he was recognized as a Distinguished Alumni of the College of Science.